Curzion Pharmaceuticals Acquired by Horizon Therapeutics

MONMOUTH JUNCTION, N.J., Oct 04, 2012 (BUSINESS WIRE) — TYRX, Inc., the leader in the commercialization of implantable medical devices intended to help reduce surgical site infections, announced today that it has received a license from Health Canada to market its AIGISRx Antibacterial Envelope. The AIGISRx Envelope is specifically designed to stabilize pacemakers and implantable defibrillators while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation.